Journal article

Homologous Recombination DNA Repair Pathway Disruption and Retinoblastoma Protein Loss Are Associated with Exceptional Survival in High-Grade Serous Ovarian Cancer

Dale W Garsed, Kathryn Alsop, Sian Fereday, Catherine Emmanuel, Catherine J Kennedy, Dariush Etemadmoghadam, Bo Gao, Val Gebski, Valerie Gares, Elizabeth L Christie, Maartje CA Wouters, Katy Milne, Joshy George, Ann-Marie Patch, Jason Li, Gisela Mir Arnau, Timothy Semple, Sreeja R Gadipally, Yoke-Eng Chiew, Joy Hendley Show all

Clinical Cancer Research | AMER ASSOC CANCER RESEARCH | Published : 2018

Grants

Awarded by Department of Health and Human Services through Victorian Cancer Agency


Awarded by National Health and Medical Research Council of Australia (NHMRC)


Awarded by Cancer Australia


Awarded by National Breast Cancer Foundation


Awarded by Canadian Institutes of Health Research


Awarded by U.S. Army Medical Research and Materiel Command


Awarded by NHMRC


Awarded by Cancer Institute New South Wales


Funding Acknowledgements

This study was financially supported by grants from the Department of Health and Human Services through the Victorian Cancer Agency (ECSG15011, to D.W. Garsed), the National Health and Medical Research Council of Australia (NHMRC; APP631701, to D.D.L. Bowtell), Cancer Australia (APP632595, to A. deFazio; APP1004673, to D.D.L. Bowtell), the National Breast Cancer Foundation (CG12-07), the Canadian Institutes of Health Research (MOP142436), the U.S. Army Medical Research and Materiel Command (W81XWH-08-1-0684 and W81XWH-08-1-0685), Cancer Australia and the National Breast Cancer Foundation (ID509303), and the Cancer Council Victoria. The Australian Ovarian Cancer Study was supported by the U.S. Army Medical Research and Materiel Command under DAMD17-01-1-0729, The Cancer Council Victoria, Queensland Cancer Fund, The Cancer Council New South Wales, The Cancer Council South Australia, The Cancer Foundation of Western Australia, The Cancer Council Tasmania and the NHMRC (ID400413 and ID400281). The AOCS gratefully acknowledges additional support from S. Boldeman, the Agar family, Ovarian Cancer Australia and the Peter MacCallum Cancer Centre Foundation. The Gynaecological Oncology Biobank at Westmead, a member of the Australasian Biospecimen Network-Oncology group, was supported by grants from the NHMRC (ID310670 and ID628903) and the Cancer Institute New South Wales (12/RIG/1-17 and 15/RIG/1-16). A. deFazio is supported by the University of Sydney Cancer Research Fund and Cancer Institute NSW, through the Sydney West Translational Cancer Research Centre.